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Background. Clostridioides (Clostridium) difficile infection (CDI) is diagnosed using clinical signs and symptoms plus positive 
laboratory tests. Recurrence of CDI after treatment is common, and coinfection with other enteric pathogens may influence clinical 
outcomes.
Methods. We aimed to assess rates of C difficile positivity, by enzyme-linked immunosorbent assay (ELISA) toxin A/B and 
BioFire FilmArray, and the effect of enteric coinfection on clinical outcomes, using samples from the EXTEND study of extended-
pulsed fidaxomicin (EPFX) versus standard vancomycin.
Results. All 356 randomized and treated patients tested positive for C difficile toxin A/B by local tests; a majority (225 of 356, 
63.2%) also tested positive by both ELISA and BioFire. Most stool samples taken at screening tested positive for C difficile only using 
BioFire (EPFX: 112 of 165, 69.7%; vancomycin: 118 of 162, 72.8%). Of the 5 patients who failed treatment and had stool samples 
available, all (1) had tested negative for C difficile by BioFire at screening and (2) were negative by ELISA at time of treatment failure. 
When analyzed by BioFire results at screening, rates of sustained clinical cure at 30 days after end of treatment were numerically 
higher with EPFX than with vancomycin for almost all patients, except for those who tested negative for C difficile but positive for 
another pathogen. However, these outcome differences by presence of coinfection did not reach statistical significance. Whole-
genome sequencing analysis determined that 20 of 26 paired samples from patients with recurrence were reinfections with the same 
C difficile strain.
Conclusions. Testing for presence of copathogens in clinical trials of antibiotics could help to explain clinical failures.
Keywords:  Clostridioides difficile; fidaxomicin; gut microbiota; infection; vancomycin.
Clostridioides (Clostridium) difficile infection (CDI) is a major 
health burden in developed countries, causing approximately 
20%–30% of antibiotic-associated diarrhea [1, 2]. The di-
agnosis of CDI is based on clinical signs and symptoms in 
combination with laboratory tests, such as cell cytotoxicity 
neutralization assay, toxigenic culture, enzyme immunoassay 
(EIA) detection of C difficile toxin A/B or glutamate dehydro-
genase (GDH), and/or nucleic acid amplification tests (NAATs) 
that detect toxin genes [3]. Because no single test is suitable 
for use as a stand-alone test for CDI, the European Society of 
Clinical Microbiology and Infectious Diseases (ESCMID) and 
the Society for Healthcare Epidemiology of America/Infectious 
Diseases Society of America guidelines recommend the use of 
a 2-step algorithm (preferably NAAT or GDH EIA, followed by 
toxin A/B EIA) to diagnose CDI [3, 4]. The NAATs that detect 
multiple pathogens simultaneously, such as the BioFire plat-
form [3], are also useful to explore the nature of the infection. 
Coinfection of C difficile and norovirus, for example, is associ-
ated with worse clinical symptoms and poorer outcomes than 
if C difficile alone was present [5]. Further characterization of 
C difficile isolates is possible with polymerase chain reaction 
(PCR) ribotyping, which can be combined with antibiotic sus-
ceptibility testing to identify isolates with reduced susceptibility 
to antibiotics [6].
Both initial and recurrent CDI follow the disruption and 
delayed recovery of normal gut microbiota, commonly as the 
result of antibiotic treatment [7–9]. Although vancomycin is 
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the standard of care for severe CDI [10], it also has a dele-
terious effect on the intestinal bacterial microbiota [11, 12], 
and approximately 24% of patients have CDI recurrence after 
vancomycin treatment [13]. Fidaxomicin, a narrow-spectrum 
macrocyclic antibiotic, has demonstrated noninferiority to 
vancomycin for initial clinical cure in Phase III clinical trials 
[14–16]. These studies also showed that fidaxomicin was as-
sociated with lower rates of recurrence compared with van-
comycin (14% versus 26%) [15], thought to be the result of 
gut microbiota preservation [8, 11, 12]. Moreover, an in vitro 
human gut model demonstrated that an extended-pulsed 
fidaxomicin (EPFX) regimen (initial twice-daily dosing for 
5  days, followed by single doses on alternate days until Day 
25)  may allow persistence of fidaxomicin at inhibitory con-
centrations for a longer time period, compared with standard 
dosing (twice-daily dosing for 10  days) [17]. In an in vitro 
gut model, this had the effect of suppressing C difficile while 
facilitating microbiota recovery [17].
The EXTEND clinical trial analyzed the efficacy of an EPFX 
regimen in patients with CDI aged 60 years and older [18], an 
age group at particular risk of CDI complications and recur-
rence [19]. Patients treated with EPFX had a significantly higher 
rate of sustained clinical cure (SCC) at 30  days after the end 
of treatment (EOT) and a significantly lower 90-day recurrence 
rate [18], compared with vancomycin. Using samples from the 
EXTEND study, we assessed the rates of C difficile toxin A/B 
positivity using a central laboratory enzyme-linked immu-
nosorbent assay (ELISA) and the effect of coinfection with 
other enteric pathogens on clinical outcomes. We also aimed 
to distinguish between recurrent CDI caused by the same C 
difficile strain as the original CDI episode (relapse) or with a 
different C difficile strain (reinfection), using whole-genome 
sequencing (WGS).
MATERIALS AND METHODS
Study Design and Patients
EXTEND was a Phase IIIb/IV randomized, controlled, 
open-label, parallel-group study conducted conducted be-
tween November 5, 2014 and May 5, 2016 at 86 centers in 21 
European countries. Full details of study methodology have 
been published previously [18]. Eligible patients included hos-
pitalized patients ≥60  years of age with clinically confirmed 
CDI (defined as >3 unformed bowel movements or ≥200 mL 
of unformed stool for patients with rectal collection devices) in 
the 24 hours before randomization plus a positive local labo-
ratory test within 48 hours of randomization for the presence 
of C difficile toxin A/B in stool. Exclusion criteria included 
CDI therapy for >1 day within the past 48 hours and >2 pre-
vious CDI episodes within 3 months of enrollment; at sites in 
Germany, patients with inflammatory bowel disease were also 
excluded. Institutional review boards at each site approved the 
study protocol and amendments, and patients provided written 
informed consent. EXTEND is registered with ClinicalTrials.
gov, number NCT02254967.
Treatments, Assessments, and Endpoints
Patients were randomized 1:1 to receive fidaxomicin (200 mg 
tablets) twice daily on Days 1–5 then once daily on alternate 
days on Days 7–25, or vancomycin (125 mg capsules) 4 times 
daily on Days 1–10 (Supplementary Figure 1) [18].
The modified full analysis set (mFAS) included all random-
ized patients who met the inclusion criteria and received ≥1 
dose of study medication. Test of cure (TOC) assessments were 
conducted 2 days after EOT (vancomycin, Day 12; EPFX, Day 
27), comprising presence of CDI, CDI severity score, and clin-
ical response, in line with ESCMID criteria [10]. The primary 
endpoint was SCC of CDI at 30  days after EOT with vanco-
mycin (Day 40) or EPFX (Day 50). Sustained clinical cure of 
CDI was defined as clinical response at TOC with no subse-
quent CDI recurrence. Recurrence was defined as diarrhea 
occurring to a greater extent than the frequency recorded at 
TOC, positive confirmation of C difficile toxin A/B, and a re-
quirement for further CDI therapy. Patients were followed up 
until Day 90. Stool samples were collected for all patients at 
screening (Day 0) and at any unscheduled visit for treatment 
failure or CDI recurrence.
Enzyme-Linked Immunosorbent Assay Detection of Clostridium 
difficile Toxin A/B in the Central Laboratory
All stool samples collected at screening and samples obtained at 
suspected treatment failure or recurrence were analyzed for the 
presence or absence of C difficile toxin A or B at a central labora-
tory (LCG, Fordham, UK), using qualitative ELISA. The result 
provided a semiquantitative measure of toxin concentration.
BioFire
All stool samples collected at screening and any stool sample 
collected at treatment failure or recurrence were analyzed at a 
central laboratory (LCG) for bacterial, parasitic, or viral enteric 
pathogens (including C difficile) using a PCR-based multiplex 
test (BioFire FilmArray Gastrointestinal Panel; bioMérieux, 
Basingstoke, UK). Patients were then categorized according to 
the BioFire result from their stool samples collected at screening: 
Group  1, positive for C difficile only; Group  2, positive for C 
difficile and another pathogen; Group 3, negative for C difficile 
but positive for another pathogen; and Group  4, negative for 
all pathogens (Supplementary Table S1). Testing for additional 
pathogens was not performed at the study sites.
Polymerase Chain Reaction Ribotyping and Antibiotic Susceptibility 
Testing
Clostridium difficile isolates were stored on Amies charcoal 
swabs and shipped at ambient temperature to the central testing 
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facility (Leeds Institute of Biomedical and Clinical Sciences, 
University of Leeds, UK). Polymerase chain reaction ribotyping 
was performed using a capillary electrophoresis-based 
ribotyping approach. The minimum inhibitory concentration 
of fidaxomicin and vancomycin was determined on the cul-
tured strains using agar dilution methods.
Whole-Genome Sequencing
To differentiate between CDI relapse and reinfection, paired 
stool samples were collected at screening and from patients 
with recurrence after TOC. Clostridium difficile isolates from 
these paired samples underwent WGS and single nucleotide 
variant (SNV) difference analysis at a central laboratory (LGC 
Genomics, Berlin, Germany). Paired isolates with ≤2 SNVs 
were considered the same C difficile strain and defined as CDI 
relapse; paired isolates with >10 SNVs were considered dif-
ferent C difficile strains and defined as CDI reinfection. Paired 
isolates with >2 but ≤10 SNVs were defined as indeterminate.
RESULTS
Patient Characteristics
The primary results of the study have been reported in full else-
where [18]. Of 364 randomized patients, 362 were included in 
the safety analysis set and 356 in the mFAS. The median age was 
75  years (Supplementary Table S2). At screening, all patients 
tested positive for C difficile toxin A/B by local laboratory test.
Clostridium difficile Toxin A/B Central Laboratory Enzyme-Linked 
Immunosorbent Assay
A similar proportion of patients in each treatment arm (EPFX: 
116 of 165, 70.3%; vancomycin: 114 of 164, 69.5%) tested pos-
itive for C difficile toxin A/B in stool samples by central lab-
oratory ELISA (Table 1). Across treatment arms, the overall 
proportion of patients who tested positive by central ELISA 
decreased to 2.3% at Day 12 then increased to 15.2% at Day 55 
(Table 1). However, the number of samples available for central 
testing was much lower at all study visits after screening. All 5 
patients who experienced treatment failure tested negative for C 
difficile toxin by central ELISA, whereas the majority of patients 
who experienced recurrence tested positive in both EPFX (8 
of 9, 88.9%) and vancomycin (18 of 25, 72.0%) treatment arms 
(Table 1).
BioFire Analysis
Proportion of Patients Positive for Clostridium difficile by BioFire
The majority of patients (287 of 356, 80.6%) tested positive for 
C difficile by BioFire at screening (Table 2). Almost all (225 of 
230, 97.8%) samples that tested positive for C difficile by ELISA 
also tested positive for C difficile by BioFire (Table 2). Across 
treatment arms, 40 of 356 (11.2%) patients tested negative for C 
difficile by BioFire (Table 2).
Proportion of Patients Positive for Other Enteric Pathogens
BioFire analysis revealed a range of enteric pathogens in stool 
samples (mFAS) taken at screening, including C difficile toxin 
A/B in 87.8% of patients (Supplementary Table S3). However, 
the majority of patients in both the EPFX (112 of 165, 69.7%) 
and vancomycin (118 of 162, 72.8%) treatment arms tested pos-
itive for C difficile only (BioFire Group 1) (Supplementary Table 
S1, Figure 1). For the group of patients who went on to experi-
ence CDI recurrence, the majority of stool samples obtained at 
screening also tested positive for C difficile only (EPFX: 7 of 9, 
77.8%; vancomycin: 15 of 24, 62.5%). Among patients who later 
experienced treatment failure, all of the stool samples obtained 
at screening tested negative for C difficile (BioFire Groups 3 and 
4) (Figure 1).
Effect of Other Enteric Pathogens on Rate of Sustained Clinical Cure
In the total mFAS, the primary efficacy endpoint of SCC 
at 30  days after EOT was significantly higher in the EPFX 
group compared with the vancomycin group (70.1% vs 59.2%; 
P  =  .030 [Cochran-Mantel-Haenszel test]) [18]. Results of 
Table 1. Proportion of Patients With Positive Result From Central 
Laboratory ELISA for Clostridioides (Clostridium) difficile Toxin A/B in 
Stool, by Study Visit (mFAS)
Visit
EPFX 
(N = 177)
Vancomycin 
(N = 179)
Total  
(N = 356)
Screening n 165 164 329
 Positive, n (%) 116 (70.3) 114 (69.5) 230 (69.9)
 Negative, n (%) 49 (29.7) 50 (30.5) 99 (30.1)
Day 5 n 27 21 48
 Positive, n (%) 5 (18.5) 5 (23.8) 10 (20.8)
 Negative, n (%) 22 (81.5) 16 (76.2) 38 (79.2)
Day 12 n 24 20 44
 Positive, n (%) 1 (4.2) 0 1 (2.3)
 Negative, n (%) 23 (95.8) 20 (100.0) 43 (97.7)
Day 27 n 20 17 37
 Positive, n (%) 1 (5.0) 3 (17.6) 4 (10.8)
 Negative, n (%) 19 (95.0) 14 (82.4) 33 (89.2)
Day 40 n 21 16 37
 Positive, n (%) 1 (4.8) 3 (18.8) 4 (10.8)
 Negative, n (%) 20 (95.2) 13 (81.3) 33 (89.2)
Day 55 n 19 14 33
 Positive, n (%) 3 (15.8) 2 (14.3) 5 (15.2)
 Negative, n (%) 16 (84.2) 12 (85.7) 28 (84.8)
Treatment failure 
(unscheduled 
visit)
n 2 3 5
 Positive, n (%) 0 0 0
 Negative, n (%) 2 (100.0) 3 (100.0) 5 (100.0)
Recurrence  
(unscheduled 
visit)
n 9 25 34
 Positive, n (%) 8 (88.9) 18 (72.0) 26 (76.5)
 Negative, n (%) 1 (11.1) 7 (28.0) 8 (23.5)
Abbreviations: ELISA, enzyme-linked immunosorbent assay; EPFX, extended-pulsed 
fidaxomicin; mFAS, modified full analysis set (all randomized patients with positive local 
laboratory test for C difficile toxin A/B at screening, who received at least 1 dose of study 
medication).
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logistic regression analyses showed that the odds of achieving 
SCC at 30 days after EOT were 68% higher in patients treated 
with EPFX compared with those treated with vancomycin 
(Supplementary Table S4).
When analyzed by BioFire patient category, rates of SCC at 
30  days after EOT were numerically higher with EPFX than 
with vancomycin for almost all patient categories except those 
who tested negative for C difficile but positive for another path-
ogen (BioFire Group 3) (Figure 2). Although there were some 
differences in SCC rates at Day 30 after EOT depending on the 
presence or absence of non-C difficile enteric pathogens (Figure 
2, Supplementary Table S4), these did not reach statistical sig-
nificance, possibly due to small sample sizes.
Characterization of Clostridium difficile Isolates
Polymerase chain reaction ribotype 027 was the most prev-
alent ribotype detected in stool samples taken at screening 
(Supplementary Table S5). For the 1 patient with PCR 
ribotyping results available from the time of treatment failure, 
PCR ribotype 126 was detected. Among the 27 patients with re-
sults available from the time of recurrence, PCR ribotypes 001, 
017, 126, and 176 were particularly prevalent. There was no 
apparent difference in C difficile susceptibility to fidaxomicin 
or vancomycin between samples taken at screening and those 
taken at recurrence (Supplementary Table S6).
Whole-Genome Sequencing
There was a significantly lower incidence of CDI recurrence in 
the EPFX arm than in the standard vancomycin arm at Days 
40 (−15.1%; P < .001), 55 (−13.9%; P < .001), and 90 (−12.8%; 
P < .001). By Day 90, a total of 45 patients (EPFX, n = 11; vanco-
mycin, n = 34) had a recurrent episode of CDI. Paired samples 
from baseline and from the time of recurrence were available 
for 26 patients. Whole-genome sequencing analysis of SNV dif-
ferences showed that the most common recurrence category 
was reinfection (>10 SNVs), occurring in 20 of 45 (44.4%) of 
these patients (Table 3). Statistical analysis of CDI relapse and 
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Figure 1. Proportions of patients at screening, with treatment failure and with recurrence, by BioFire categorization (mFAS). BioFire groupings were based on results at 
screening: Group 1, positive for Clostridium difficile only; Group 2, positive for C difficile and another pathogen; Group 3, negative for C difficile but positive for another path-
ogen; Group 4, negative for all pathogens. Percentages are calculated over the number of patients in both treatment arms at screening, who had treatment failure or who had 
recurrence, respectively. Data for treatment failure and recurrence are given up to Day 90. EPFX, extended-pulsed fidaxomicin; mFAS, modified full analysis set (all randomized 
patients with positive local laboratory test for C difficile toxin A/B at screening, who received at least 1 dose of study medication).
Table 2. Number of Positive Test Results for Clostridioides (Clostridium) 
difficile at Screening From Central Laboratory ELISA Versus BioFire (mFAS)
Patient 
group ELISA Result
BioFire Result
Positive Negative Missing Total
All patients Positive 225 4 1 230
 Negative 61 36 2 99
 Missing 1 0 26 27
 Total 287 40 29 356
EPFX Positive 112 3 1 116
 Negative 29 20 0 49
 Missing 1 0 11 12
 Total 142 23 12 177
Vancomycin Positive 113 1 0 114
 Negative 32 16 2 50
 Missing 0 0 15 15
 Total 145 17 17 179
Abbreviations: ELISA, enzyme-linked immunosorbent assay; EPFX, extended-pulsed 
fidaxomicin; mFAS, modified full analysis set (all randomized patients with positive local 
laboratory test for C difficile toxin A/B at screening, who received at least 1 dose of study 
medication).
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reinfection according to SNV differences was not possible 
owing to the small number of paired samples available.
DISCUSSION
In this secondary analysis of data from the EXTEND study, we used 
microbiological techniques to explore the nature of initial CDI and 
the effect of enteric coinfection on the rate of SCC. Although all pa-
tients in the mFAS tested positive for C difficile toxin A/B by local 
laboratory test (in line with study inclusion criteria), not all tested 
positive by central laboratory ELISA or BioFire. Of 356 patients 
included in the mFAS, 61 tested negative by central ELISA but 
positive by BioFire, whereas 4 tested positive by central ELISA but 
negative by BioFire. A total of 225 (63.2%) patients tested positive 
for C difficile by both methods. Given that the assays have different 
targets, these data suggest that BioFire has a greater sensitivity for C 
difficile detection compared with toxin A/B ELISA.
The proportion of patients who tested positive for C difficile 
toxin A/B by central ELISA appeared to decrease during the 
course of EPFX or vancomycin treatment. It was notable that all 
patients who experienced treatment failure tested negative for 
C difficile toxin by central ELISA at the time of their treatment 
failure visit, whereas a high proportion of patients with recur-
rence tested positive. However, conclusions from these data are 
limited due to low sample numbers. Likewise, although some 
differences in prevalent PCR ribotypes were observed between 
samples taken at screening and samples from the time of recur-
rence, numbers were too small to draw any conclusions.
Although a range of pathogens were detected across the 
stool samples obtained at screening, the majority of patients 
(87.8%) tested positive for C difficile alone. A  number of pa-
tients (11.2%) tested negative for C difficile by BioFire analysis 
of samples obtained at screening, despite having tested positive 
by local CDI tests. It is possible that this finding may account 
for some of the patients who experienced treatment failure: of 
the 5 patients who experienced treatment failure and had stool 
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Figure 2. Sustained clinical cure of Clostridioides (Clostridium) difficile infection at 30 days after end of treatment by BioFire results at screening (mFAS). BioFire groups 
are based on results at screening: Group 1, positive for C difficile only; Group 2, positive for C difficile and another pathogen; Group 3, negative for C difficile but positive for 
another pathogen; Group 4, negative for all pathogens. a, P value derived from Cochran-Mantel-Haenszel test, adjusting for baseline stratification factors. b, P value derived 
from χ 2 test. mFAS, modified full analysis set (all randomized patients with positive local laboratory test for C difficile toxin A/B at screening, who received at least 1 dose 
of study medication); N/A, not available. 
Table 3. Clostridioides (Clostridium) difficile Infection Relapse and 
Reinfection Results at Day 90 (mFAS)
Treatment arm EPFX Vancomycin Total
Patients with CDI recurrence n = 11 n = 34 n = 45
Patients in mFAS 177 179 356
Tested pairs, n (%)a 7 (15.6) 19 (42.2) 26 (57.8)
 Relapse (≤2 SNV) 1 (2.2) 3 (6.7) 4 (8.9)
 Reinfection (>10 SNV) 5 (11.1) 15 (33.3) 20 (44.4)
 Indeterminate (>2 but ≤10 SNV) 1 (2.2) 1 (2.2) 2 (4.4)
No SNV results available, n (%) 4 (8.9) 15 (33.3) 19 (42.2)
Abbreviations: CDI, C difficile infection; EPFX, extended-pulsed fidaxomicin; mFAS, modi-
fied full analysis set (all randomized patients with positive local laboratory test for C difficile 
toxin A/B at screening who received at least one dose of study medication); SNV, single 
nucleotide variant.
aPercentages are calculated over the total number of patients who experienced CDI recur-
rence in both treatment arms.
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sample results available, all 5 were negative for C difficile at 
screening according to BioFire results, and all 5 tested negative 
for C difficile by central ELISA of samples taken at treatment 
failure. This outcome suggests that the local C difficile test re-
sults for some of these patients were false positives. It is also 
possible that the ELISA used in the central laboratory was less 
sensitive than that used in local laboratories, or that there was 
sample degradation during long-term storage before central 
testing could be conducted. Post hoc analysis of the primary 
outcome on these BioFire-determined C difficile-negative pa-
tients was not conducted using central ELISA-determined re-
sults, because BioFire was deemed the more sensitive test.
For the overall mFAS population, the rate of SCC at Day 30 
after EOT was significantly superior in patients treated with 
EPFX versus vancomycin. The superior effect of EPFX was 
observed in all BioFire groups except for patients who tested 
negative for C difficile but positive for another pathogen. In 
both the EPFX and vancomycin treatment arms, numerically 
higher rates of SCC were observed in patients who tested pos-
itive for other pathogens in addition to C difficile (BioFire 
grouping 2 + 3), compared with those who either tested positive 
for C difficile only or were negative for all pathogens (BioFire 
grouping “1 + 4”). Although sample sizes were too low to reach 
statistical significance, the potential link between clinical out-
come and BioFire result suggests that BioFire may be a useful 
diagnostic tool to complement local CDI testing and to identify 
patients most likely to respond to particular treatments.
According to analysis of SNV differences, most incidences 
of recurrent CDI were reinfections. This finding contrasts with 
previous WGS analyses of isolates from both Phase III clinical 
trials [20] and hospitalized patients with recurrent CDI [21], 
which found higher rates of relapse than reinfection. Previous 
clinical trial data [14, 16, 20] also demonstrated a significant 
improvement with fidaxomicin over vancomycin with regard 
to rate of relapse. However, the small number of paired sam-
ples (n = 26) in the present EXTEND study limited our ability 
to provide a definitive assessment of relapse versus reinfection 
rates. In addition, our results are not directly comparable to pre-
vious studies due to differences in study design and outcome 
criteria, particularly because both previous Phase III trials used 
the standard fidaxomicin regimen (200 mg of fidaxomicin twice 
daily for 10 days), whereas the EXTEND study used the EPFX 
regimen. In addition, patients were followed up until Day 40 in 
the Phase III trials [14, 16] and until Day 90 in the EXTEND 
study [18].
Limitations of this study include possible analysis bias be-
cause some patients remained in the hospital for CDI treatment, 
giving rise to the potential for increased exposure to other C 
difficile strains circulating within the hospital and an enhanced 
probability of reinfection rather than relapse. In addition, the 
BioFire results should be interpreted with caution due to small 
sample sizes and the possibility that pathogens may be carried 
(and detected) without being the cause of the diarrhea in these 
patients.
CONCLUSIONS
In conclusion, the BioFire platform may prove to be a useful tool 
to identify other enteric pathogens that may influence clinical 
outcomes in C difficile-related studies. These analyses of micro-
biological data from the EXTEND trial showed higher rates of 
SCC at 30  days after EOT with EPFX compared with vanco-
mycin, in all patients except for those who tested negative for 
C difficile by BioFire and positive for another pathogen. Testing 
for the presence of copathogens should be considered in clinical 
trials of antibiotics because they could help to explain clinical 
failures.
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